Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of 6MW3211 injection in advanced malignant tumors
CTR20211936Phase 2Terminated
- Sponsor
- Maiwei Biotech
- Start
- Sep 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of 6MW3211 in Non-hematologic malignancy, sponsored by Maiwei Biotech. Started Sep 2021; status: terminated.
02
Drugs
6MW3211
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on CTR20211936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211936.